Rituximab, Mycophenolate Mofetil Compared for Pemphigus Vulgaris

WEDNESDAY, May 19, 2021 -- For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news